“On July 21, 2008, I had a life changing opportunity. It’s now been over three and a half years, and I still find it difficult to believe that I am really one of those people who have had an islet cell transplant.”
Medtronic focuses on three components of the AP: a glucose sensor, an insulin delivery device, and an algorithm to govern their behavior. Each component in this trinity plays a crucial role in making the system work.
The current thinking around following a high fat, low carb diet to encourage weight loss in diabetics with Type 2 Diabetes, may be misguided say researchers from Warwick Medical School.
In clinical trials, doctors transplanted insulin-making cells to her pancreas
Researchers have gained federal approval for the next key testing phase for a new, University of Virginia-designed, cell phone-based artificial pancreas they hope could soon help millions of diabetes patients.
Australian scientists have identified one way of making a frustratingly tricky transplant – of insulin-producing ‘islets of Langerhans’ into patients with Type 1 diabetes – more successful.
In their fight to cure diabetes, Mayo Clinic and University of Minnesota researchers are creating a tiny, innovative sensing system as part of an artificial pancreas.
Indiana researchers are working on an artificial pancreas, a device they say could be the first step in reaching a cure for diabetes.
Practical Cure, as defined by the JDCA, outlines a specified goal for research to work towards in order to accelerate the development of a tangible, cure-like lifestyle for people now living with diabetes.
Medical device companies are racing to be the first to market an artificial pancreas, which takes over the work of the diabetic’s malfunctioning organ. The device could potentially be used for Type 1 diabetics or Type 2 diabetics who use insulin.
According to a press release, data from an in-clinic study demonstrated that patients using the company’s MiniMed Paradigm System with Low Glucose Suspend automation experienced a 19% reduction in time spent below the low glucose threshold compared with those using conventional pump therapy.
In a study published this month in Diabetes Technology & Therapeutics, researchers concluded that the automatic suspension of insulin delivery by a low glucose suspend (LGS) system greatly reduces the severity and duration of hypoglycemia in people with type 1 diabetes.
Charles Zimliki is a biologist who works at FDA. He’s an important person for all PWDs to know about in that he has a key role in developing the technology that will one day become a functioning Artificial Pancreas.
Feb 7th 2011. On December 1, the U.S. Food and Drug Administration (FDA) issued artificial pancreas (AP) draft guidance. This is a necessary first to make this technology avalaible to the public.